Filter
505
Text search:
Pre-exposure
Prophylaxis
Featured
Recommendations
53
New Publications
117
Language
Document type
No document type
261
Guidelines
123
Studies & Reports
72
Manuals
13
Strategic & Response Plan
13
Fact sheets
13
Infographics
5
Training Material
2
Situation Updates
1
Resource Platforms
1
Countries / Regions
South Africa
18
Kenya
15
Zambia
12
Asia
11
Uganda
10
Global
10
Namibia
9
Nigeria
7
Malawi
7
Africa
6
Eastern Europe
6
Philippines
5
India
5
Ukraine
5
Sierra Leone
4
Ghana
4
Nepal
4
Russia
4
Zimbabwe
3
Brazil
3
Lesotho
3
Myanmar / Burma
3
Latin America and the Carribbean
3
Georgia
3
Liberia
2
Ethiopia
2
Tanzania
2
North Macedonia
2
Botswana
2
East and Southern Africa
2
South–East Asia Region
2
Western and Central Europe
2
Armenia
2
Guinea-Bissau
1
Cameroon
1
Germany
1
Rwanda
1
Bangladesh
1
Mozambique
1
Eswatini/ Swaziland
1
Angola
1
Middle East and North Africa
1
Paraguay
1
Belgium
1
Belarus
1
Authors & Publishers
Publication Years
Category
Countries
115
Clinical Guidelines
41
Women & Child Health
21
Public Health
9
Key Resources
5
Pharmacy & Technologies
2
Toolboxes
HIV
324
COVID-19
14
TB
11
Caregiver
7
NTDs
5
Rapid Response
4
Pharmacy
4
Health Financing Toolbox
4
Mental Health
3
Planetary Health
3
Ebola & Marburg
2
Polio
2
Global Health Education
2
AMR
2
Conflict
1
Refugee
1
NCDs
1
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention o
...
Esc Anna Nery 2024;28:e20240093
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex C
The Lancet HIV. Volume 12, Issue 10e712-e721October 2025. This article from The Lancet HIV estimates the impact of the PEPFAR funding pause for PrEP on HIV infections in sub-Saharan Africa.
The new WHO recommendations for rabies immunization supersede the 2010 WHO position
on pre-exposure prophylaxis (PrEP) and post-exposure
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex D
Mathematical modelling of lenacapavir: landscaping review on impact and cost–effectiveness
recommended
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex E
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex F
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex G Abstract
Adolescent girls and young women (AGYW) remain disproportionately affected by HIV in Eastern and Southern Africa (ESA), with 26 per cent of new infections attributed to this population. AGYW face many personal, social and structural barriers to access, uptake and use of traditional HIV prevention me
...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-
...
3 June 2021. After 40 years of AIDS, charting a course to end the pandemic.
The report shows that countries with progressive laws and policies and strong and inclusive health systems have had the best outcomes against HIV. In those countries, people living with and affected by HIV are more likely t
...